Monday, 18 December 2017
Latest news
Main » Citigroup Now Covering Abeona Therapeutics (NASDAQ:ABEO) With $32 Target

Citigroup Now Covering Abeona Therapeutics (NASDAQ:ABEO) With $32 Target

12 October 2017

Therefore 100% are positive.

Taking a broader look at the analyst consensus, according to 6 analysts Abeona Therapeutics (NASDAQ:ABEO)'s price will reach at $23 during 52 weeks. $22.43's average target is 19.63% above currents $18.75 stock price. Abeona Therapeutics Inc had 9 analyst reports since April 13, 2017 according to SRatingsIntel. 1 is equivalent to a buy rating, 3 a hold rating, and 5 a sell rating. The stock has a consensus rating of "Buy" and a consensus target price of $21.44.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Tuesday, August 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. The firm has "Buy" rating by Maxim Group given on Wednesday, August 16. As per Wednesday, December 16, the company rating was initiated by Maxim Group. The stock of Abeona Therapeutics Inc (NASDAQ:ABEO) earned "Buy" rating by Maxim Group on Thursday, September 29. H.C. Wainwright maintained the stock with "Buy" rating in Friday, September 8 report.

More news: 'Breaking Bad' Fans Keep Throwing Pizza on Walter White's House

W.W. Grainger, Inc.is a distributor of maintenance, fix and operating (MRO) supplies and other related services and products.

However looking at valuation ratios the stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0. The Firm operates through two divisions, which include the United States and Canada. The rating was downgraded by Societe Generale on Thursday, September 1 to "Hold". A stock with a price that fluctuates wildly, hits new highs and lows or moves erratically is considered highly volatile.

In the transaction dated January 26, 2015, the great number of shares acquired came courtesy the Director; Ahn Mark J added a total of 25,000 shares at an average price of $4, amounting to approximately $100,000.

More news: 'FEMA cannot stay in Puerto Rico forever!'

9/14/2017-Royal Bank Of Canada initiated coverage with a Outperform rating. The stock has "Buy" rating by H.C. Wainwright on Wednesday, July 19. Argent Capital Mgmt Ltd Co holds 0.54% of its portfolio in General Electric Company (NYSE:GE) for 499,710 shares. Coho Partners Ltd. owns 693,866 shares or 3.13% of their U.S. portfolio. Wellington Management Group LLP now owns 204,590 shares of the biopharmaceutical company's stock worth $1,023,000 after purchasing an additional 30,300 shares during the period. Moving averages are used as a strong indicator for technical stock analysis and it helps investors in figuring out where the stock has been and also facilitate in determining where it may be possibly heading. Citigroup, New York-based fund reported 6.07 million shares. 20, 2016. These shares are worth $27,400 and were traded at $5.48 each. It has underperformed by 16.70% the S&P500.

Analysts await W W Grainger Inc (NYSE:GWW) to report earnings on October, 17 before the open. The total number of shares traded in the last 90-day period is 0. After $-0.21 actual earnings per share reported by Abeona Therapeutics Inc for the previous quarter, Wall Street now forecasts -23.81% EPS growth. The share last price represents uptick move of 5.56% in value from company's 52-Week high price and shows 392.59% above change in value from its 52-Week low price.

Abeona Therapeutics Inc. focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The company has market cap of $829.92 million. On average, equities research analysts predict that Abeona Therapeutics will post ($0.68) earnings per share for the current fiscal year. It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy for rare blood diseases.

More news: Chris Johnson's Forecast | Showers and storms set to increase

Citigroup Now Covering Abeona Therapeutics (NASDAQ:ABEO) With $32 Target